Off-label use of tumor necrosis factor inhibitors on ankylosing spondylitis, ulcerative colitis, and psoriasis.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D054598:Blue Cross Blue Shield Insurance Plans; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease; D016207:Cytokines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine; D006801:Humans; D011356:Product Labeling; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D016207:Cytokines; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha